radiation induced oral mucositis riom in head and neck cancer hnc epidemiology forecast insight

DelveInsight’s ‘Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) Understanding

Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) is one of the major ionizing radiation toxicities and normal tissue injuries that result from radiotherapy. RIOM is a normal tissue injury lasting between 7 and 98 days, which starts as an acute inflammation of the oral mucosa, tongue, and pharynx after radiotherapy (RT) exposure. Radiation-induced mucositis is initiated by direct injury to basal epithelial cells and cells in the underlying tissue. DNA-strand breaks can result in cell death or injury.

 

RIOM is a major dose-limiting toxicity in head and neck cancer (HNC) patients. It is a normal tissue injury caused by radiation/RT, which has marked adverse effects on patient quality of life and cancer therapy continuity. It is a challenge for radiation oncologists since it leads to cancer therapy interruption, poor local tumor control, and changes in dose fractionation. RIOM occurs in 100% of altered fractionation radiotherapy HNC patients.

 

HNCs include cancers in the larynx, throat, lips, mouth, nose, and salivary glands. Tobacco use, heavy alcohol use, and infection with human papillomavirus (HPV) increase the risk of head and neck cancers. Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). These cancers are referred to as squamous cell carcinomas of the head and neck. HNCs can also begin in the salivary glands, sinuses, or muscles or nerves in the head and neck, but these types of cancer are much less common than squamous cell carcinomas.

 

Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) patients can progress to an acute life-threatening stage due to severe physical obstruction of food and water intake with subsequent weight loss and septic complication due to lost protective epithelial and basement membrane barriers. All of this leads to limitations of local tumor control due to cancer treatment interruption and alterations in radiation dose fractionation. The stages of progression of RIOM are initial hyperemia and erythema during the pre-ulcer phase. There is a release of various pro-inflammatory cytokines from epithelial, vascular, and connective tissue cells at the site of tissue injury. This is followed by the epithelial phase with various degrees of desquamation and basement membrane damage with loss of the protective barrier, which ends with the physical appearance of the ulceration. Secondary infection with Gram-negative bacteria or yeast may occur, with micro coagulation of the vasculature that worsens the inflammation by the local ischemia with more necrotic tissue yield. The final stage will be the healing phase and fibrosis.

Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) Diagnosis

Clinical signs of mucosal damage and cell death appear after the first 1–2 weeks of radiation therapy. Initial mucosal damage results in patchy erythema, edema, atrophy, and whitening of the mucosal tissue with increased sensitivity – patients report a burning sensation in the mouth.  Further mucosal epithelium loss occurs in the fourth or fifth week of conventionally fractionated radiation, resulting in fibrinous exudation, confluent inflammation, and ulceration. Mouth sores and swelling can cause severe oral pain, swallowing difficulties, weight loss, and dehydration. Mucosal injury makes the patient more susceptible to oral-super infection, which causes more discomfort, changes in taste and appetite, and a lower quality of life.

 

Diagnosis is based on the symptoms the patient is experiencing and the appearance of the mouth’s tissues following bone marrow transplants or radiotherapy. Red burn-like sores or ulcers throughout the mouth are enough to diagnose mucositis. Oral mucositis is typically diagnosed based on the appearance, location, and timing of oral lesions, as well as the medical history, which may show a medication or treatment form that is highly linked with Oral Mucositis. Useful laboratory studies for confirming diagnosis and etiology, especially if the infection is suspected, are as follows. CBC Count, viral culture and fungal testing etc.

Epidemiology Perspective by DelveInsight

The Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology division provides insights about historical and current Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2020, the total incident cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) was 129.67 K cases in the 7MM which are expected to grow during the study period, i.e., 2021-2034.

 

The disease epidemiology covered in the report provides historical as well as forecasted Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology [segmented as Total Incident Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC), Total Grade-specific Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC), and Total Treated Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) Epidemiology

Estimates show that the highest cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) in the 7MM were in the United States, followed by the Japan, France, Germany, the United Kingdom, Italy, and Spain in 2020.

• In the United States, the total number of incident cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) was 50.82 K cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.
• In the year 2020, the total incident cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) were 58.91 K cases in EU-5 which are expected to grow during the study period, i.e., 2021-2034.
• In Japan, the total number of incident cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) was 19.95 K cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.

Scope of the Report

• The Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) Report and Model provide an overview of the risk factors and global trends of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC).
• The report provides the segmentation of the Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology by total incident cases in the 7MM.
• The report provides the segmentation of the Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology by total grade-specific cases in the 7MM.
• The report provides the segmentation of the Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology by total treated cases in the 7MM.

Report Highlights

• 10-Year Forecast of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology
• 7MM Coverage
• Total Incident Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC)
• Total Grade-Specific Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC)
• Total Treated Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC)

KOL-Views

We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC)?
• What are the key findings of the Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology across the 7MM and which country will have the highest number of patients during the study period (2021-2034)?
• What would be the total number of patients of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) across the 7MM during the study period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2021-2034)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2021-2034)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC)?

Reasons to buy

The Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) market
• Quantify patient populations in the global Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) therapeutics in each of the markets covered
• Understand the magnitude of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) population by its age group-specificity
• The Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population